Last reviewed 2026-05-15 · How we verify

Mycophenolate mofetil Tab./Cap.

Mycophenolate mofetil Tab./Cap. is a Immunosuppressant; IMPDH inhibitor Small molecule drug developed by Chong Kun Dang Pharmaceutical. It is currently FDA-approved for Prevention of organ rejection in renal, cardiac, and hepatic transplant recipients, Active lupus nephritis, Active rheumatoid arthritis (as adjunctive therapy).

Mycophenolate mofetil is a prodrug that inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation.

Mycophenolate mofetil is a prodrug that inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent organ rejection. Used for Prevention of organ rejection in patients receiving allogeneic renal, cardiac, or hepatic transplants, Treatment of active lupus nephritis.

At a glance

Mechanism of action

Mycophenolate mofetil is rapidly converted to mycophenolic acid (MPA), its active form, which preferentially inhibits IMPDH type II, an enzyme critical for guanosine nucleotide synthesis in lymphocytes. By depleting guanosine nucleotides, MPA selectively suppresses the proliferation of T and B cells while having minimal effects on other cell types, making it an effective immunosuppressant. This mechanism makes it particularly useful in preventing organ rejection and treating autoimmune conditions.

Approved indications

• Prevention of organ rejection in renal, cardiac, and hepatic transplant recipients
• Active lupus nephritis
• Active rheumatoid arthritis (as adjunctive therapy)

Common side effects

• Diarrhea
• Leukopenia
• Anemia
• Infection
• Nausea
• Vomiting
• Abdominal pain
• Tremor

Key clinical trials

• Study to Compare the Efficacy and Safety After Conversion to RaparoBell® or My-Rept® in Kidney Transplant Patients (PHASE4)
• Optimizing PTCy Dose and Timing (PHASE1, PHASE2)
• Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants (PHASE4)
• Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy (PHASE3)
• Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea (PHASE4)
• Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol (PHASE4)
• MYREPTIC-N® or MY-REPT® in Stable Patients After Kidney Transplant Recipients (PHASE4)
• Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Mycophenolate mofetil Tab./Cap. CI brief — competitive landscape report
• Mycophenolate mofetil Tab./Cap. updates RSS · CI watch RSS
• Chong Kun Dang Pharmaceutical portfolio CI

Frequently asked questions about Mycophenolate mofetil Tab./Cap.

Related

• Drug class: All Immunosuppressant; IMPDH inhibitor drugs
• Target: All drugs targeting Inosine monophosphate dehydrogenase (IMPDH) type II
• Manufacturer: Chong Kun Dang Pharmaceutical — full pipeline
• Therapeutic area: All drugs in Immunology; Transplantation
• Indication: Drugs for Prevention of organ rejection in renal, cardiac, and hepatic transplant recipients
• Indication: Drugs for Active lupus nephritis
• Indication: Drugs for Active rheumatoid arthritis (as adjunctive therapy)

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing